Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Global health experts have united in a call for governments and international organisations around the world to plan strategically for the coordinated production, equitable distribution and surveillance of COVID-19 medical products to ensure access to quality-assured medications for everyone.

Coronavirus close-up © NIH

The comment piece, published in The Lancet Global Health, was signed by 55 signatories from across 20 countries.

Enormous emergency efforts are underway to find optimal medical products, to prevent, diagnose, and treat COVID-19, which approximately 7.8 billion people will depend on. With significant disruption of pharmaceutical production and supply, and increasing numbers of falsified and substandard products, strategic planning is needed now to ensure global access to quality-assured medical products and monitoring of supply chains.

Co-author Professor Paul Newton, who leads Medicine Quality at IDDO, said: ‘Vital interventions are needed to ensure global manufacture, access, protection, and monitoring of supply chains.

The full story is available on the IDDO website

Similar stories

Rise in COPCOV numbers continues; study to end recruitment 30 Nov

A global study examining the impact of chloroquine / hydroxychloroquine in preventing COVID-19, COPCOV has recruited 3,386 participants as of 26 Oct from sites in Benin, Côte d’Ivoire, Indonesia, Kenya, Mali, Nepal, Pakistan, Zambia, and closed sites in Thailand, Niger and the UK. Last week, the COPCOV team agreed with active site research teams that it will continue to recruit new participants until 30 Nov 2021, with preliminary study results expected Q1 2022.

Lack of evidence is key barrier to using portable devices to detect poor quality medicines

A series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.

New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Researchers call for access to Ivermectin for young children

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.